Palisade Bio (PALI) Receivables - Net (2011 - 2026)

Palisade Bio (PALI) posted quarterly Receivables - Net of $250000.0 for Q1 2023, up 323.73% quarter-over-quarter from $59000.0 in Q2 2021.

Palisade Bio (PALI) Receivables - Net (2011 - 2026) Analysis & Trends

Palisade Bio (PALI) has reported Receivables - Net for 12 consecutive years, with $250000.0 the latest figure, recorded in Q1 2023.

In Q1 2023, Receivables - Net changed N/A year-over-year to $250000.0; the TTM figure through Mar 2023 stood at $250000.0 (changed N/A YoY), while the FY2020 annual figure was $59000.0, up 180.1% from the prior year.
Receivables - Net rose to $250000.0 in Q1 2023 per PALI's latest filing, from $59000.0 in the prior quarter.
Across five years, Receivables - Net topped out at $250000.0 in Q1 2023 and bottomed at $8779.0 in Q3 2020.
Historically, Receivables - Net has averaged $84354.1 across 4 years, with a median of $59000.0 in 2020.
Annual changes were most pronounced in 2019 — Receivables - Net plunged 92.84% — and 2021, when it jumped 248.33%.
Palisade Bio's Receivables - Net stood at $21064.0 in 2019, then jumped by 180.1% to $59000.0 in 2020, then changed by 0.0% to $59000.0 in 2021, then surged by 323.73% to $250000.0 in 2023.
Business Quant data shows PALI's Receivables - Net at $250000.0 in Q1 2023, $59000.0 in Q2 2021, and $25259.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Palisade Bio	372.94 Mn	247.74 Mn	-

Download Data